Recent Posts
- US FDA Grants Once Daily Dosing Option For NITYR (nitisinone) Tablets for HT-1 Patients
- Dr David Buckeridge Joins Cycle Pharmaceuticals’ Board of Directors
- Cycle Pharmaceuticals Features in the Sunday Times Tech Track Ones to Watch 2020
- Cycle Pharmaceuticals Secures $25 Million Debt Financing
- Cycle Launches COVID-19 Response For Eligible Patients with Tyrosinemia Type 1 (HT-1)
Archives
-
-
Dr David Buckeridge Joins Cycle Pharmaceuticals’ Board of DirectorsSeptember 8th, 2020 -
Cycle Pharmaceuticals Features in the Sunday Times Tech Track Ones to Watch 2020September 8th, 2020
- No comments have been published yet.
Find us on Facebook
Archives
Recent Posts
- US FDA Grants Once Daily Dosing Option For NITYR (nitisinone) Tablets for HT-1 Patients
- Dr David Buckeridge Joins Cycle Pharmaceuticals’ Board of Directors
- Cycle Pharmaceuticals Features in the Sunday Times Tech Track Ones to Watch 2020
- Cycle Pharmaceuticals Secures $25 Million Debt Financing
- Cycle Launches COVID-19 Response For Eligible Patients with Tyrosinemia Type 1 (HT-1)
Recent Comments